Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ArmiClenz
- Development stage
- Unknown
- Lead developer
- Armis Biopharma
- Modality
- Small Molecules, Device-based Delivery → Drug Delivery Systems
- Administration
- Topical
01
Overview
ArmiClenz is an EPA-registered, clinical-grade surface disinfectant and topical antimicrobial solution developed by Armis Biopharma. It is based on the proprietary Veriox technology platform, which utilizes a peracid and hydrogen peroxide-based formulation to provide broad-spectrum antimicrobial activity. Designed as a multi-surface disinfectant, sanitizer, and deodorizer, ArmiClenz is effective against a wide range of pathogens, including 99% of SARS-CoV-2 and Human Rhinovirus 42, on non-porous surfaces. The product is non-toxic, safe for use on all surfaces, and environmentally friendly. It does not contribute to antimicrobial resistance due to its oxidative mechanism of action and is intended for use in medical facilities, homes, offices, and food production environments.
- Brand names
- ArmiClenz
- Other names
- ArmiClenz disinfectant
02
Targets
Chitin
Beyond the preview
Go deeper on ArmiClenz.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ArmiClenz.